HSA
ALNY icon

HBK Sorce Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

HBK Sorce Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,306
Closed -$310K – 601
2022
Q4 		$310K Buy
+1,306
New +$279K 0.01% 552

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

HBK Sorce Advisory's ALNY Position: Q1 2023 in Review

HBK Sorce Advisory sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2023, closing a stake of 1,306 shares — an estimated $310K sold.

HBK Sorce Advisory first reported a position in ALNY in Q4 2022 and held it in 1 quarter. The position peaked at $310K in Q4 2022. 477 funds tracked by Wall St. Rank hold ALNY as of Q1 2023.

  • HBK Sorce Advisory reported no remaining Alnylam Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • HBK Sorce Advisory sold 1,306 Alnylam Pharmaceuticals shares in Q1 2023, an estimated $310K.
  • HBK Sorce Advisory first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • HBK Sorce Advisory's Alnylam Pharmaceuticals position peaked at $310K in Q4 2022.
  • 477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2023.

Based on HBK Sorce Advisory's 13F filing for Q1 2023, filed 15 May 2023.